Share This Page
Drugs in ATC Class R01AB
✉ Email this page to a colleague
Drugs in ATC Class: R01AB - Sympathomimetics, combinations excl. corticosteroids
ATC Class R01AB (Sympathomimetics, combinations excluding corticosteroids) market dynamics and patent landscape
ATC R01AB covers intranasal sympathomimetic combination products (excluding corticosteroids). Public patent and FDA Orange Book granularity is typically by specific branded drug, active ingredient, dosage form, and strength; the class-level universe is heterogeneous, and many key exclusivity issues are product-specific rather than class-wide. Without a defined list of R01AB marketed products to map to Orange Book listings and patent families, a complete, accurate class-wide patent landscape (patent numbers, expiration dates, Paragraph IV risk, litigation, settlement terms, and FDA exclusivity) cannot be produced from reliable sources.
Which branded intranasal R01AB sympathomimetic combinations have FDA exclusivity and Orange Book patents?
A class-level answer is not feasible because FDA Orange Book and patent term calculations apply to individual NDA/BLA products, not to ATC subclasses. For R01AB, the practical patent landscape is driven by the specific active combination (for example, “decongestant + decongestant” or “decongestant + antiallergy agent” depending on labeling) and whether the product is an NDA, Rx, OTC, or switch to monograph.
What products define R01AB in the US market?
Featured snippets and litigation risk analyses depend on the exact:
- Drug name as listed in Orange Book
- NDA holder and application number
- Dosage form (metered spray vs drops)
- Strengths and formulation identifiers used for patent mapping
Without the marketed product list, the Orange Book status and patent term expiry cannot be enumerated.
When do R01AB sympathomimetic combination patents expire, and what drives generic entry timing?
Generic entry timing usually depends on a layered stack:
- Patent expiration (composition, formulation, device/actuator, manufacturing)
- FDA patent certifications (and court outcomes) tied to each Orange Book listing
- Statutory and regulatory exclusivities (5-year NCE, 3-year new clinical investigations, pediatric exclusivity, orphan exclusivity where applicable)
- OTC vs Rx pathway (where relevant to regulatory exclusivity structure)
A class-wide “when” cannot be computed without product-specific patent expiry dates, listed patents, and certification histories.
What typically blocks generics for intranasal sympathomimetic combinations?
Common technical IP blockers in this space include:
- Formulation patents for pH, osmolarity, buffer systems, viscosity agents, preservatives
- Delivery device and plume control patents for metered-dose sprays or pump-actuators
- Manufacturing process patents for mixing order, particle control, and fill accuracy
These are again product-specific and must be anchored to named Orange Book entries.
How many patents cover R01AB sympathomimetic combinations, and how strong are the estates by claim type?
Patent-counting and strength scoring require:
- Exact patent family identification per product
- Claim scope mapping to generic design-around feasibility
- Litigation history per asserted patents
- Jurisdiction (US patents only vs global family)
A “how many” metric at ATC class level cannot be accurate because:
- Multiple active combinations can fall inside the same ATC class
- Many products can be non-exclusive or have already passed patent expiry
- Some key IP can sit in device or process patents that do not appear in Orange Book for every product
What formulation patents protect intranasal sympathomimetic combination sprays and drops in R01AB?
Formulation IP for intranasal combination products tends to cluster into:
- Buffer and pH range control to stabilize active ingredients
- Preservative compatibility and antimicrobial system selection
- Solubilizers and tonicity agents
- Viscosity modifiers that affect spray droplet size and deposition
- Particle size or emulsion stability controls when relevant
To convert this into a defensible patent landscape, the analysis must identify the specific marketed R01AB products and their associated formulation patents from patent databases and/or Orange Book-listed patents. Class-only coverage would be incomplete.
What method-of-use or dosing regimen patents exist for R01AB sympathomimetic combinations?
Method-of-use IP can include:
- Indication-specific dosing frequency
- Pediatric or adult regimen constraints
- Treatment windows linked to disease severity or onset timing
- Combination-use claims (timing of co-administration of components)
These claims are highly product-specific and often depend on how labeling was written at approval. Without the product set, the method-of-use landscape cannot be enumerated.
Which companies hold the key R01AB patent estates and what is their geographic coverage?
Geographic coverage analysis requires:
- Identifying assignees by patent family
- Mapping country filings (US, EP, JP, CN, KR, IN where relevant)
- Tracking continuation/divisional filings and term adjustments
A class-level list of assignees would mix unrelated families and misstate ownership.
What patent litigation and Paragraph IV challenges affect generic entry for R01AB combinations?
Paragraph IV risk is tied to:
- Specific Orange Book patent certifications (four required forms: Section 505(b)(2) references differ; ANDA must certify to each Orange Book patent)
- District court case number and asserted patents
- Settlement agreement dates and 30-month stay expiries
Without named Orange Book products and their listed patents, there is no defensible way to list the Paragraph IV challenges or characterize litigation outcomes.
What are the FDA regulatory statuses of intranasal R01AB sympathomimetic combinations (NDA vs OTC monograph), and how does that change exclusivity?
For market dynamics, the regulatory status determines:
- Whether FDA grants exclusivity (NDA pathways)
- Whether ANDAs or 505(b)(2) applications are possible
- Whether the product follows OTC monograph rules (where patent exclusivity is less central)
ATC classes in the decongestant and intranasal space often include OTC-available actives where the IP and regulatory pathway differ from prescription NDAs. A class-level status map cannot be produced accurately without the underlying product list.
How do R01AB sympathomimetic combinations compare with R01AA/R01AC and R01AB alternatives in patent barriers and switch risk?
Competitive dynamics depend on direct substitutes:
- Other intranasal decongestant combinations in adjacent ATC codes
- Formulation changes (spray vs drops, different combinations)
- Switching between Rx and OTC
Patent barriers can differ materially across substitute classes due to different actives and different approval histories. A comparative patent map requires specific branded products across multiple ATC codes.
Key takeaways
- A reliable class-wide patent landscape for ATC R01AB cannot be produced without mapping the ATC subclass to the specific marketed drug products that have FDA Orange Book listings.
- Patent expiration, Paragraph IV risk, litigation, and exclusivity timing are product-specific; ATC-class aggregation would misstate expiry dates and overcount or undercount patent estates.
- Formulation, method-of-use, and device/process IP are the dominant blockers in intranasal combinations, but they must be anchored to named products to identify the controlling patent families and enforceable claim scope.
- Competitive timing and generic entry risk require a product-by-product substitution set across adjacent ATC intranasal categories.
FAQs
- How do Orange Book patent listings for intranasal combination decongestants determine ANDA Paragraph IV certifications?
- What patent claim types most commonly survive generic design-arounds for intranasal metered sprays?
- How do pediatric exclusivity and patent term adjustments shift generic launch for intranasal products?
- What role do device and actuator patents play in intranasal spray formulation IP enforcement?
- When is a 505(b)(2) pathway preferable to an ANDA for intranasal sympathomimetic combination products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/
- FDA. Drugs@FDA. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency (EMA). ATC classification and medicines information resources. https://www.ema.europa.eu/
More… ↓
